Pharmaceuticals: Global Industry Almanac, MarketLine

NEW YORK, Jan. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceuticals: Global Industry Almanac, MarketLine

http://www.reportlinker.com/p01080559/Pharmaceuticals-Global-Industry-Almanac-MarketLine.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.

Scope of the Report

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Covers the Global, European and Asia-Pacific markets as well as individual chapters on Australia, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Norway, Poland, Russia, Singapore, South Africa, South Korea, Spain, Sweden, United Kingdom and United States.

* Includes a five-year forecast of the industry

Highlights

The global pharmaceuticals market grew by 3.5% in 2011 to reach a value of $782.1 billion.

In 2016, the global pharmaceuticals market is forecast to have a value of $971.1 billion, an increase of 24.2% since 2011.

Americas accounts for 42.2% of the global pharmaceuticals market value.

Pfizer is the leading player in the global pharmaceuticals market, generating a 8.7% share of the market's value.

Why you should buy this report

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.TABLE OF CONTENTSEXECUTIVE SUMMARY 2Market value 2Market value forecast 2Geography segmentation 2Market share 2Introduction 35What is this report about? 35Who is the target reader? 35How to use this report 35Definitions 35Global Pharmaceuticals 36Market Overview 36Market Data 37Market Segmentation 38Market outlook 40Five forces analysis 41Pharmaceuticals in Asia-Pacific 49Market Overview 49Market Data 50Market Segmentation 51Market outlook 53Five forces analysis 54Pharmaceuticals in Europe 62Market Overview 62Market Data 63Market Segmentation 64Market outlook 66Five forces analysis 67Pharmaceuticals in France 75Market Overview 75Market Data 76Market Segmentation 77Market outlook 79Five forces analysis 80Macroeconomic indicators 88Pharmaceuticals in Germany 90Market Overview 90Market Data 91Market Segmentation 92Market outlook 94Five forces analysis 95Macroeconomic indicators 103Pharmaceuticals in Australia 105Market Overview 105Market Data 106Market Segmentation 107Market outlook 109Five forces analysis 110Macroeconomic indicators 118Pharmaceuticals in Belgium 120Market Overview 120Market Data 121Market Segmentation 122Market outlook 124Five forces analysis 125Macroeconomic indicators 133Pharmaceuticals in Brazil 135Market Overview 135Market Data 136Market Segmentation 137Market outlook 139Five forces analysis 140Macroeconomic indicators 148Pharmaceuticals in Canada 150Market Overview 150Market Data 151Market Segmentation 152Market outlook 154Five forces analysis 155Macroeconomic indicators 163Pharmaceuticals in China 165Market Overview 165Market Data 166Market Segmentation 167Market outlook 169Five forces analysis 170Macroeconomic indicators 178Pharmaceuticals in The Czech Republic 180Market Overview 180Market Data 181Market Segmentation 182Market outlook 184Five forces analysis 185Macroeconomic indicators 193Pharmaceuticals in Denmark 195Market Overview 195Market Data 196Market Segmentation 197Market outlook 199Five forces analysis 200Macroeconomic indicators 208Pharmaceuticals in Hungary 210Market Overview 210Market Data 211Market Segmentation 212Market outlook 214Five forces analysis 215Macroeconomic indicators 223Pharmaceuticals in India 225Market Overview 225Market Data 226Market Segmentation 227Market outlook 229Five forces analysis 230Macroeconomic indicators 238Pharmaceuticals in Italy 240Market Overview 240Market Data 241Market Segmentation 242Market outlook 244Five forces analysis 245Macroeconomic indicators 253Pharmaceuticals in Japan 255Market Overview 255Market Data 256Market Segmentation 257Market outlook 259Five forces analysis 260Macroeconomic indicators 268Pharmaceuticals in Mexico 270Market Overview 270Market Data 271Market Segmentation 272Market outlook 274Five forces analysis 275Macroeconomic indicators 283Pharmaceuticals in The Netherlands 285Market Overview 285Market Data 286Market Segmentation 287Market outlook 289Five forces analysis 290Macroeconomic indicators 298Pharmaceuticals in Norway 300Market Overview 300Market Data 301Market Segmentation 302Market outlook 304Five forces analysis 305Macroeconomic indicators 313Pharmaceuticals in Poland 315Market Overview 315Market Data 316Market Segmentation 317Market outlook 319Five forces analysis 320Macroeconomic indicators 328Pharmaceuticals in Russia 330Market Overview 330Market Data 331Market Segmentation 332Market outlook 334Five forces analysis 335Macroeconomic indicators 343Pharmaceuticals in Singapore 345Market Overview 345Market Data 346Market Segmentation 347Market outlook 349Five forces analysis 350Macroeconomic indicators 358Pharmaceuticals in South Africa 360Market Overview 360Market Data 361Market Segmentation 362Market outlook 364Five forces analysis 365Macroeconomic indicators 373Pharmaceuticals in South Korea 375Market Overview 375Market Data 376Market Segmentation 377Market outlook 379Five forces analysis 380Macroeconomic indicators 388Pharmaceuticals in Spain 390Market Overview 390Market Data 391Market Segmentation 392Market outlook 394Five forces analysis 395Macroeconomic indicators 403Pharmaceuticals in Sweden 405Market Overview 405Market Data 406Market Segmentation 407Market outlook 409Five forces analysis 410Macroeconomic indicators 418Pharmaceuticals in The United Kingdom 420Market Overview 420Market Data 421Market Segmentation 422Market outlook 424Five forces analysis 425Macroeconomic indicators 433Pharmaceuticals in The United States 435Market Overview 435Market Data 436Market Segmentation 437Market outlook 439Five forces analysis 440Macroeconomic indicators 448Company Profiles 450Leading companies 450Appendix 538Methodology 538

LIST OF TABLES

Table 1: Global pharmaceuticals market value: $ billion, 2007–11 37

Table 2: Global pharmaceuticals market geography segmentation: $ billion, 2011 38

Table 3: Global pharmaceuticals market share: % share, by value, 2011 39

Table 4: Global pharmaceuticals market value forecast: $ billion, 2011–16 40

Table 5: Asia-Pacific pharmaceuticals market value: $ billion, 2007–11 50

Table 6: Asia–Pacific pharmaceuticals market geography segmentation: $ billion, 2011 51

Table 7: Asia-Pacific pharmaceuticals market share: % share, by value, 2011 52

Table 8: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2011–16 53

Table 9: Europe pharmaceuticals market value: $ billion, 2007–11 63

Table 10: Europe pharmaceuticals market geography segmentation: $ billion, 2011 64

Table 11: Europe pharmaceuticals market share: % share, by value, 2011 65

Table 12: Europe pharmaceuticals market value forecast: $ billion, 2011–16 66

Table 13: France pharmaceuticals market value: $ billion, 2007–11 76

Table 14: France pharmaceuticals market geography segmentation: $ billion, 2011 77

Table 15: France pharmaceuticals market share: % share, by value, 2011 78

Table 16: France pharmaceuticals market value forecast: $ billion, 2011–16 79

Table 17: France size of population (million), 2007–11 88

Table 18: France gdp (constant 2000 prices, $ billion), 2007–11 88

Table 19: France gdp (current prices, $ billion), 2007–11 88

Table 20: France inflation, 2007–11 89

Table 21: France consumer price index (absolute), 2007–11 89

Table 22: France exchange rate, 2007–11 89

Table 23: Germany pharmaceuticals market value: $ billion, 2007–11 91

Table 24: Germany pharmaceuticals market geography segmentation: $ billion, 2011 92

Table 25: Germany pharmaceuticals market share: % share, by value, 2011 93

Table 26: Germany pharmaceuticals market value forecast: $ billion, 2011–16 94

Table 27: Germany size of population (million), 2007–11 103

Table 28: Germany gdp (constant 2000 prices, $ billion), 2007–11 103

Table 29: Germany gdp (current prices, $ billion), 2007–11 103

Table 30: Germany inflation, 2007–11 104

Table 31: Germany consumer price index (absolute), 2007–11 104

Table 32: Germany exchange rate, 2007–11 104

Table 33: Australia pharmaceuticals market value: $ billion, 2007–11 106

Table 34: Australia pharmaceuticals market geography segmentation: $ billion, 2011 107

Table 35: Australia pharmaceuticals market share: % share, by value, 2011 108

Table 36: Australia pharmaceuticals market value forecast: $ billion, 2011–16 109

Table 37: Australia size of population (million), 2007–11 118

Table 38: Australia gdp (constant 2000 prices, $ billion), 2007–11 118

Table 39: Australia gdp (current prices, $ billion), 2007–11 118

Table 40: Australia inflation, 2007–11 119

Table 41: Australia consumer price index (absolute), 2007–11 119

Table 42: Australia exchange rate, 2007–11 119

Table 43: Belgium pharmaceuticals market value: $ billion, 2007–11 121

Table 44: Belgium pharmaceuticals market geography segmentation: $ billion, 2011 122

Table 45: Belgium pharmaceuticals market share: % share, by value, 2011 123

Table 46: Belgium pharmaceuticals market value forecast: $ billion, 2011–16 124

Table 47: Belgium size of population (million), 2007–11 133

Table 48: Belgium gdp (constant 2000 prices, $ billion), 2007–11 133

Table 49: Belgium gdp (current prices, $ billion), 2007–11 133

Table 50: Belgium inflation, 2007–11 134

Table 51: Belgium consumer price index (absolute), 2007–11 134

Table 52: Belgium exchange rate, 2007–11 134

Table 53: Brazil pharmaceuticals market value: $ billion, 2007–11 136

Table 54: Brazil pharmaceuticals market geography segmentation: $ billion, 2011 137

Table 55: Brazil pharmaceuticals market share: % share, by value, 2011 138

Table 56: Brazil pharmaceuticals market value forecast: $ billion, 2011–16 139

Table 57: Brazil size of population (million), 2007–11 148

Table 58: Brazil gdp (constant 2000 prices, $ billion), 2007–11 148

Table 59: Brazil gdp (current prices, $ billion), 2007–11 148

Table 60: Brazil inflation, 2007–11 149

Table 61: Brazil consumer price index (absolute), 2007–11 149

Table 62: Brazil exchange rate, 2007–11 149

Table 63: Canada pharmaceuticals market value: $ billion, 2007–11 151

Table 64: Canada pharmaceuticals market geography segmentation: $ billion, 2011 152

Table 65: Canada pharmaceuticals market share: % share, by value, 2011 153

Table 66: Canada pharmaceuticals market value forecast: $ billion, 2011–16 154

Table 67: Canada size of population (million), 2007–11 163

Table 68: Canada gdp (constant 2000 prices, $ billion), 2007–11 163

Table 69: Canada gdp (current prices, $ billion), 2007–11 163

Table 70: Canada inflation, 2007–11 164

Table 71: Canada consumer price index (absolute), 2007–11 164

Table 72: Canada exchange rate, 2007–11 164

Table 73: China pharmaceuticals market value: $ billion, 2007–11 166

Table 74: China pharmaceuticals market geography segmentation: $ billion, 2011 167

Table 75: China pharmaceuticals market share: % share, by value, 2011 168

Table 76: China pharmaceuticals market value forecast: $ billion, 2011–16 169

Table 77: China size of population (million), 2007–11 178

Table 78: China gdp (constant 2000 prices, $ billion), 2007–11 178

Table 79: China gdp (current prices, $ billion), 2007–11 178

Table 80: China inflation, 2007–11 179

Table 81: China consumer price index (absolute), 2007–11 179

Table 82: China exchange rate, 2007–11 179

Table 83: Czech Republic pharmaceuticals market value: $ billion, 2007–11 181

Table 84: Czech Republic pharmaceuticals market geography segmentation: $ billion, 2011 182

Table 85: Czech Republic pharmaceuticals market share: % share, by value, 2011 183

Table 86: Czech Republic pharmaceuticals market value forecast: $ billion, 2011–16 184

Table 87: Czech Republic size of population (million), 2007–11 193

Table 88: Czech Republic gdp (constant 2000 prices, $ billion), 2007–11 193

Table 89: Czech Republic gdp (current prices, $ billion), 2007–11 193

Table 90: Czech Republic inflation, 2007–11 194

Table 91: Czech Republic consumer price index (absolute), 2007–11 194

Table 92: Czech Republic exchange rate, 2007–11 194

Table 93: Denmark pharmaceuticals market value: $ billion, 2007–11 196

Table 94: Denmark pharmaceuticals market geography segmentation: $ billion, 2011 197

Table 95: Denmark pharmaceuticals market share: % share, by value, 2011 198

Table 96: Denmark pharmaceuticals market value forecast: $ billion, 2011–16 199

Table 97: Denmark size of population (million), 2007–11 208

Table 98: Denmark gdp (constant 2000 prices, $ billion), 2007–11 208

Table 99: Denmark gdp (current prices, $ billion), 2007–11 208

Table 100: Denmark inflation, 2007–11 209

Table 101: Denmark consumer price index (absolute), 2007–11 209

Table 102: Denmark exchange rate, 2007–11 209

Table 103: Hungary pharmaceuticals market value: $ billion, 2007–11 211

Table 104: Hungary pharmaceuticals market geography segmentation: $ billion, 2011 212

Table 105: Hungary pharmaceuticals market share: % share, by value, 2011 213

Table 106: Hungary pharmaceuticals market value forecast: $ billion, 2011–16 214

Table 107: Hungary size of population (million), 2007–11 223

Table 108: Hungary gdp (constant 2000 prices, $ billion), 2007–11 223

Table 109: Hungary gdp (current prices, $ billion), 2007–11 223

Table 110: Hungary inflation, 2007–11 224

Table 111: Hungary consumer price index (absolute), 2007–11 224

Table 112: Hungary exchange rate, 2007–11 224

Table 113: India pharmaceuticals market value: $ billion, 2007–11 226

Table 114: India pharmaceuticals market geography segmentation: $ billion, 2011 227

Table 115: India pharmaceuticals market share: % share, by value, 2011 228

Table 116: India pharmaceuticals market value forecast: $ billion, 2011–16 229

Table 117: India size of population (million), 2007–11 238

Table 118: India gdp (constant 2000 prices, $ billion), 2007–11 238

Table 119: India gdp (current prices, $ billion), 2007–11 238

Table 120: India inflation, 2007–11 239

Table 121: India consumer price index (absolute), 2007–11 239

Table 122: India exchange rate, 2007–11 239

Table 123: Italy pharmaceuticals market value: $ billion, 2007–11 241

Table 124: Italy pharmaceuticals market geography segmentation: $ billion, 2011 242

Table 125: Italy pharmaceuticals market share: % share, by value, 2011 243

Table 126: Italy pharmaceuticals market value forecast: $ billion, 2011–16 244

Table 127: Italy size of population (million), 2007–11 253

Table 128: Italy gdp (constant 2000 prices, $ billion), 2007–11 253

Table 129: Italy gdp (current prices, $ billion), 2007–11 253

Table 130: Italy inflation, 2007–11 254

Table 131: Italy consumer price index (absolute), 2007–11 254

Table 132: Italy exchange rate, 2007–11 254

Table 133: Japan pharmaceuticals market value: $ billion, 2007–11 256

Table 134: Japan pharmaceuticals market geography segmentation: $ billion, 2011 257

Table 135: Japan pharmaceuticals market share: % share, by value, 2011 258

Table 136: Japan pharmaceuticals market value forecast: $ billion, 2011–16 259

Table 137: Japan size of population (million), 2007–11 268

Table 138: Japan gdp (constant 2000 prices, $ billion), 2007–11 268

Table 139: Japan gdp (current prices, $ billion), 2007–11 268

Table 140: Japan inflation, 2007–11 269

Table 141: Japan consumer price index (absolute), 2007–11 269

Table 142: Japan exchange rate, 2007–11 269

Table 143: Mexico pharmaceuticals market value: $ billion, 2007–11 271

Table 144: Mexico pharmaceuticals market geography segmentation: $ billion, 2011 272

Table 145: Mexico pharmaceuticals market share: % share, by value, 2011 273

Table 146: Mexico pharmaceuticals market value forecast: $ billion, 2011–16 274

Table 147: Mexico size of population (million), 2007–11 283

Table 148: Mexico gdp (constant 2000 prices, $ billion), 2007–11 283

Table 149: Mexico gdp (current prices, $ billion), 2007–11 283

Table 150: Mexico inflation, 2007–11 284

Table 151: Mexico consumer price index (absolute), 2007–11 284

Table 152: Mexico exchange rate, 2007–11 284

Table 153: Netherlands pharmaceuticals market value: $ million, 2007–11 286

Table 154: Netherlands pharmaceuticals market geography segmentation: $ million, 2011 287

Table 155: Netherlands pharmaceuticals market share: % share, by value, 2011 288

Table 156: Netherlands pharmaceuticals market value forecast: $ million, 2011–16 289

Table 157: Netherlands size of population (million), 2007–11 298

Table 158: Netherlands gdp (constant 2000 prices, $ billion), 2007–11 298

Table 159: Netherlands gdp (current prices, $ billion), 2007–11 298

Table 160: Netherlands inflation, 2007–11 299

Table 161: Netherlands consumer price index (absolute), 2007–11 299

Table 162: Netherlands exchange rate, 2007–11 299

Table 163: Norway pharmaceuticals market value: $ billion, 2007–11 301

Table 164: Norway pharmaceuticals market geography segmentation: $ billion, 2011 302

Table 165: Norway pharmaceuticals market share: % share, by value, 2011 303

Table 166: Norway pharmaceuticals market value forecast: $ billion, 2011–16 304

Table 167: Norway size of population (million), 2007–11 313

Table 168: Norway gdp (constant 2000 prices, $ billion), 2007–11 313

Table 169: Norway gdp (current prices, $ billion), 2007–11 313

Table 170: Norway inflation, 2007–11 314

Table 171: Norway consumer price index (absolute), 2007–11 314

Table 172: Norway exchange rate, 2007–11 314

Table 173: Poland pharmaceuticals market value: $ billion, 2007–11 316

Table 174: Poland pharmaceuticals market geography segmentation: $ billion, 2011 317

Table 175: Poland pharmaceuticals market share: % share, by value, 2011 318

Table 176: Poland pharmaceuticals market value forecast: $ billion, 2011–16 319

Table 177: Poland size of population (million), 2007–11 328

Table 178: Poland gdp (constant 2000 prices, $ billion), 2007–11 328

Table 179: Poland gdp (current prices, $ billion), 2007–11 328

Table 180: Poland inflation, 2007–11 329

Table 181: Poland consumer price index (absolute), 2007–11 329

Table 182: Poland exchange rate, 2007–11 329

Table 183: Russia pharmaceuticals market value: $ billion, 2007–11 331

Table 184: Russia pharmaceuticals market geography segmentation: $ billion, 2011 332

Table 185: Russia pharmaceuticals market share: % share, by value, 2011 333

Table 186: Russia pharmaceuticals market value forecast: $ billion, 2011–16 334

Table 187: Russia size of population (million), 2007–11 343

Table 188: Russia gdp (constant 2000 prices, $ billion), 2007–11 343

Table 189: Russia gdp (current prices, $ billion), 2007–11 343

Table 190: Russia inflation, 2007–11 344

Table 191: Russia consumer price index (absolute), 2007–11 344

Table 192: Russia exchange rate, 2007–11 344

Table 193: Singapore pharmaceuticals market value: $ million, 2007–11 346

Table 194: Singapore pharmaceuticals market geography segmentation: $ million, 2011 347

Table 195: Singapore pharmaceuticals market share: % share, by value, 2011 348

Table 196: Singapore pharmaceuticals market value forecast: $ million, 2011–16 349

Table 197: Singapore size of population (million), 2007–11 358

Table 198: Singapore gdp (constant 2000 prices, $ billion), 2007–11 358

Table 199: Singapore gdp (current prices, $ billion), 2007–11 358

Table 200: Singapore inflation, 2007–11 359

Table 201: Singapore consumer price index (absolute), 2007–11 359

Table 202: Singapore exchange rate, 2007–11 359

Table 203: South Africa pharmaceuticals market value: $ billion, 2007–11 361

Table 204: South Africa pharmaceuticals market geography segmentation: $ million, 2007–2011 362

Table 205: South Africa pharmaceuticals market share: % share, by value, 2011 363

Table 206: South Africa pharmaceuticals market value forecast: $ billion, 2011–16 364

Table 207: South Africa size of population (million), 2007–11 373

Table 208: South Africa gdp (constant 2000 prices, $ billion), 2007–11 373

Table 209: South Africa gdp (current prices, $ billion), 2007–11 373

Table 210: South Africa inflation, 2007–11 374

Table 211: South Africa consumer price index (absolute), 2007–11 374

Table 212: South Africa exchange rate, 2007–11 374

Table 213: South Korea pharmaceuticals market value: $ billion, 2007–11 376

Table 214: South Korea pharmaceuticals market geography segmentation: $ billion, 2011 377

Table 215: South Korea pharmaceuticals market share: % share, by value, 2011 378

Table 216: South Korea pharmaceuticals market value forecast: $ billion, 2011–16 379

Table 217: South Korea size of population (million), 2007–11 388

Table 218: South Korea gdp (constant 2000 prices, $ billion), 2007–11 388

Table 219: South Korea gdp (current prices, $ billion), 2007–11 388

Table 220: South Korea inflation, 2007–11 389

Table 221: South Korea consumer price index (absolute), 2007–11 389

Table 222: South Korea exchange rate, 2007–11 389

Table 223: Spain pharmaceuticals market value: $ billion, 2007–11 391

Table 224: Spain pharmaceuticals market geography segmentation: $ billion, 2011 392

Table 225: Spain pharmaceuticals market share: % share, by value, 2011 393

Table 226: Spain pharmaceuticals market value forecast: $ billion, 2011–16 394

Table 227: Spain size of population (million), 2007–11 403

Table 228: Spain gdp (constant 2000 prices, $ billion), 2007–11 403

Table 229: Spain gdp (current prices, $ billion), 2007–11 403

Table 230: Spain inflation, 2007–11 404

Table 231: Spain consumer price index (absolute), 2007–11 404

Table 232: Spain exchange rate, 2007–11 404

Table 233: Sweden pharmaceuticals market value: $ billion, 2007–11 406

Table 234: Sweden pharmaceuticals market geography segmentation: $ billion, 2011 407

Table 235: Sweden pharmaceuticals market share: % share, by value, 2011 408

Table 236: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 409

Table 237: Sweden size of population (million), 2007–11 418

Table 238: Sweden gdp (constant 2000 prices, $ billion), 2007–11 418

Table 239: Sweden gdp (current prices, $ billion), 2007–11 418

Table 240: Sweden inflation, 2007–11 419

Table 241: Sweden consumer price index (absolute), 2007–11 419

Table 242: Sweden exchange rate, 2007–11 419

Table 243: United Kingdom pharmaceuticals market value: $ billion, 2007–11 421

Table 244: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2011 422

Table 245: United Kingdom pharmaceuticals market share: % share, by value, 2011 423

Table 246: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16 424

Table 247: United Kingdom size of population (million), 2007–11 433

Table 248: United Kingdom gdp (constant 2000 prices, $ billion), 2007–11 433

Table 249: United Kingdom gdp (current prices, $ billion), 2007–11 433

Table 250: United Kingdom inflation, 2007–11 434

Table 251: United Kingdom consumer price index (absolute), 2007–11 434

Table 252: United Kingdom exchange rate, 2007–11 434

Table 253: United States pharmaceuticals market value: $ billion, 2007–11 436

Table 254: United States pharmaceuticals market geography segmentation: $ billion, 2011 437

Table 255: United States pharmaceuticals market share: % share, by value, 2011 438

Table 256: United States pharmaceuticals market value forecast: $ billion, 2011–16 439

Table 257: United States size of population (million), 2007–11 448

Table 258: United States gdp (constant 2000 prices, $ billion), 2007–11 448

Table 259: United States gdp (current prices, $ billion), 2007–11 448

Table 260: United States inflation, 2007–11 449

Table 261: United States consumer price index (absolute), 2007–11 449

Table 262: United States exchange rate, 2007–11 449

Table 263: Pfizer Inc.: key facts 450

Table 264: Pfizer Inc.: key financials ($) 451

Table 265: Pfizer Inc.: key financial ratios 451

Table 266: GlaxoSmithKline Plc: key facts 453

Table 267: GlaxoSmithKline Plc: key financials ($) 454

Table 268: GlaxoSmithKline Plc: key financials (£) 455

Table 269: GlaxoSmithKline Plc: key financial ratios 455

Table 270: AstraZeneca PLC: key facts 457

Table 271: AstraZeneca PLC: key financials ($) 458

Table 272: AstraZeneca PLC: key financial ratios 459

Table 273: Merck & Co., Inc.: key facts 461

Table 274: Merck & Co., Inc.: key financials ($) 462

Table 275: Merck & Co., Inc.: key financial ratios 462

Table 276: Daiichi Sankyo Co., Ltd.: key facts 464

Table 277: Daiichi Sankyo Co., Ltd.: key financials ($) 465

Table 278: Daiichi Sankyo Co., Ltd.: key financials (¥) 465

Table 279: Daiichi Sankyo Co., Ltd.: key financial ratios 465

Table 280: Astellas Pharma Inc.: key facts 467

Table 281: Astellas Pharma Inc.: key financials ($) 468

Table 282: Astellas Pharma Inc.: key financials (¥) 468

Table 283: Astellas Pharma Inc.: key financial ratios 468

Table 284: Novartis AG: key facts 470

Table 285: Novartis AG: key financials ($) 471

Table 286: Novartis AG: key financial ratios 471

Table 287: Aché Laboratórios Farmacêuticos S.A.: key facts 473

Table 288: Medley Indústria Farmacêutica Ltd: key facts 474

Table 289: Sanofi: key facts 475

Table 290: Sanofi: key financials ($) 476

Table 291: Sanofi: key financials (€) 476

Table 292: Sanofi: key financial ratios 476

Table 293: EMS Sigma Pharma: key facts 478

Table 294: Johnson & Johnson: key facts 479

Table 295: Johnson & Johnson: key financials ($) 480

Table 296: Johnson & Johnson: key financial ratios 480

Table 297: Jiangsu Yangtze River Pharmaceutical Group Company Ltd.: key facts 482

Table 298: Orifarm A/S: key facts 483

Table 299: Gedeon Richter Plc: key facts 484

Table 300: Gedeon Richter Plc: key financials ($) 485

Table 301: Gedeon Richter Plc: key financials (HUF) 485

Table 302: Gedeon Richter Plc: key financial ratios 485

Table 303: EGIS Pharmaceuticals Plc: key facts 487

Table 304: EGIS Pharmaceuticals Plc: key financials ($) 488

Table 305: EGIS Pharmaceuticals Plc: key financials (HUF) 488

Table 306: EGIS Pharmaceuticals Plc: key financial ratios 488

Table 307: Dr. Reddy's Laboratories Limited: key facts 490

Table 308: Dr. Reddy's Laboratories Limited: key financials ($) 491

Table 309: Dr. Reddy's Laboratories Limited: key financials (Rs.) 491

Table 310: Dr. Reddy's Laboratories Limited: key financial ratios 491

Table 311: Cipla Limited: key facts 493

Table 312: Cipla Limited: key financials ($) 494

Table 313: Cipla Limited: key financials (Rs.) 494

Table 314: Cipla Limited: key financial ratios 494

Table 315: Ranbaxy Laboratories Limited: key facts 496

Table 316: Ranbaxy Laboratories Limited: key financials ($) 497

Table 317: Ranbaxy Laboratories Limited: key financials (Rs.) 497

Table 318: Ranbaxy Laboratories Limited: key financial ratios 497

Table 319: Lupin Limited: key facts 499

Table 320: Lupin Limited: key financials ($) 500

Table 321: Lupin Limited: key financials (Rs.) 500

Table 322: Lupin Limited: key financial ratios 501

Table 323: Chiesi Farmaceutici S.P.A.: key facts 503

Table 324: Menarini Group, The: key facts 505

Table 325: Takeda Pharmaceutical Company Limited: key facts 506

Table 326: Takeda Pharmaceutical Company Limited: key financials ($) 507

Table 327: Takeda Pharmaceutical Company Limited: key financials (¥) 507

Table 328: Takeda Pharmaceutical Company Limited: key financial ratios 507

Table 329: Mitsubishi Tanabe Pharma Corporation: key facts 509

Table 330: Mitsubishi Tanabe Pharma Corporation: key financials ($) 510

Table 331: Mitsubishi Tanabe Pharma Corporation: key financials (¥) 510

Table 332: Mitsubishi Tanabe Pharma Corporation: key financial ratios 510

Table 333: Eli Lilly and Company: key facts 512

Table 334: Eli Lilly and Company: key financials ($) 513

Table 335: Eli Lilly and Company: key financial ratios 513

Table 336: Polpharma SA: key facts 515

Table 337: Pharmstandard OJSC: key facts 516

Table 338: Pharmstandard OJSC: key financials ($) 516

Table 339: Pharmstandard OJSC: key financials (RUB) 517

Table 340: Pharmstandard OJSC: key financial ratios 517

Table 341: Bayer AG: key facts 519

Table 342: Bayer AG: key financials ($) 520

Table 343: Bayer AG: key financials (€) 520

Table 344: Bayer AG: key financial ratios 521

Table 345: Aspen Pharmacare Holdings Ltd: key facts 523

Table 346: Aspen Pharmacare Holdings Ltd: key financials ($) 524

Table 347: Aspen Pharmacare Holdings Ltd: key financials (ZAR) 524

Table 348: Aspen Pharmacare Holdings Ltd: key financial ratios 524

Table 349: Daewoong Pharmaceutical Co., Ltd.: key facts 526

Table 350: Daewoong Pharmaceutical Co., Ltd.: key financials ($) 527

Table 351: Daewoong Pharmaceutical Co., Ltd.: key financials (KRW) 527

Table 352: Daewoong Pharmaceutical Co., Ltd.: key financial ratios 527

Table 353: Hanmi Holdings Co., Ltd.: key facts 529

Table 354: Hanmi Holdings Co., Ltd.: key financials ($) 530

Table 355: Hanmi Holdings Co., Ltd.: key financials (KRW) 530

Table 356: Hanmi Holdings Co., Ltd.: key financial ratios 530

Table 357: Dong-A Pharmaceutical Co., Ltd.: key facts 532

Table 358: Dong-A Pharmaceutical Co., Ltd.: key financials ($) 532

Table 359: Dong-A Pharmaceutical Co., Ltd.: key financials (KRW) 533

Table 360: Dong-A Pharmaceutical Co., Ltd.: key financial ratios 533

Table 361: Almirall S.A.: key facts 535

Table 362: Almirall S.A.: key financials ($) 535

Table 363: Almirall S.A.: key financials (€) 536

Table 364: Almirall S.A.: key financial ratios 536

To order this report:Pharmaceutical Industry: Pharmaceuticals: Global Industry Almanac, MarketLine

CONTACT
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker